ClearPoint Neuro, Inc.

During the quarter ended June 30, 2025, the following Section 16 officers adopted Rule 10b5-1 trading arrangements, as defined in Item 408(a) of Regulation S-K:

•

Joseph M. Burnett, our Chief Executive Officer and President, adopted a new Rule 10b5-1 trading arrangement on June 11, 2025. The plan's maximum duration is until September 30, 2026, and first trades will not occur until October 10, 2025 at the earliest. The trading plan is intended to permit Mr. Burnett to exercise and sell from time to time: (i) a total of 100,000 stock options set to expire on November 7, 2027 in five tranches of 20,000 each, and (ii) a total of 51,200 shares of common stock currently held in Mr. Burnett's trust.

•

Lynnette C. Fallon, a member of our Board of Directors, adopted a new Rule 10b5-1 trading arrangement on June 11, 2025. The plan's maximum duration is until December 31, 2026, and first trades will not occur until October 10, 2025 at the earliest. The trading plan is intended to permit Ms. Fallon to sell shares of common stock to cover income taxes due in conjunction with the vesting of the annual director grant which vests on the earlier of: (i) May 22, 2026, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. The maximum shares to be sold is 5,091.

The Rule 10b5-1 trading arrangements described above were adopted and precleared in accordance with the Company's Insider Trading Policy and actual sale transactions made pursuant to such trading arrangements will be disclosed publicly in future Section 16 filings with the SEC.

No other directors or officers adopted, modified, orterminated a Rule 10b5-1 trading arrangement as defined in Item 408(a) of Regulation S-K during the last fiscal quarter.